Core Viewpoint - Zai Lab has entered into a strategic collaboration and licensing agreement with AbbVie for the global development and commercialization of ZG006 (Alveltamig), retaining rights in Greater China while granting AbbVie exclusive rights outside this region [1] Group 1: Agreement Details - AbbVie will receive exclusive development and commercialization rights for ZG006 outside of Greater China, which includes mainland China, Hong Kong, and Macau [1] - Zai Lab will receive an upfront payment of $100 million, along with milestone payments based on clinical progress and additional payments related to the licensing option, totaling up to $60 million [1] - If AbbVie exercises the licensing option, Zai Lab is eligible for up to $1.075 billion in milestone payments and will receive tiered royalties ranging from high single digits to mid-teens on net sales of the product outside Greater China [1]

Core Viewpoint - Zai Lab has entered into a strategic collaboration and licensing agreement with AbbVie for the global development and commercialization of ZG006 (Alveltamig), retaining rights in Greater China while granting AbbVie exclusive rights outside this region [1] Group 1: Agreement Details - AbbVie will receive exclusive development and commercialization rights for ZG006 outside of Greater China, which includes mainland China, Hong Kong, and Macau [1] - Zai Lab will receive an upfront payment of $100 million, along with milestone payments based on clinical progress and additional payments related to the licensing option, totaling up to $60 million [1] - If AbbVie exercises the licensing option, Zai Lab is eligible for up to $1.075 billion in milestone payments and will receive tiered royalties ranging from high single digits to mid-teens based on net sales of the product outside Greater China [1]

Core Viewpoint - Zai Jian Pharmaceutical has entered into a strategic collaboration and licensing agreement with AbbVie for the global development and commercialization of ZG006 (Alveltamig), retaining rights in Greater China while granting AbbVie exclusive rights outside this region [1] Group 1: Agreement Details - AbbVie will pay Zai Jian a $100 million upfront payment, with potential milestone payments of up to $60 million based on clinical progress [1] - If AbbVie exercises its licensing option, Zai Jian could receive up to $1.075 billion in milestone payments and tiered royalties ranging from high single digits to mid-double digits on net sales outside Greater China [1] Group 2: Product Information - ZG006 is a novel trispecific T-cell engager targeting DLL3, currently in late-stage clinical development for small cell lung cancer and other DLL3-expressing malignancies [1] - The drug has received clinical trial approval from the FDA and NMPA, and has been designated as a breakthrough therapy for relapsed or progressive advanced small cell lung cancer and DLL3-positive neuroendocrine carcinoma by NMPA [1] - ZG006 has also been granted orphan drug designation by the FDA [1]

Core Viewpoint - Zejing Pharmaceutical (688266.SH) has entered into a strategic cooperation and licensing option agreement with AbbVie for the global development and commercialization of ZG006 (Alveltamig) [1] Group 1: Agreement Details - AbbVie has obtained exclusive rights for the development and commercialization of ZG006 outside of Greater China, while Zejing retains rights within Greater China [1] - Zejing will receive an upfront payment of $100 million, along with milestone payments based on clinical progress and licensing options totaling up to $60 million [1] - If AbbVie exercises the licensing option, Zejing is eligible for up to $1.075 billion in milestone payments and will receive tiered royalties ranging from high single digits to mid-double digits on net sales of the product outside Greater China [1]